Notably, the relative contributions of effector function (ADCC/CDC/ADCP) and the inhibition of CD70's interaction with CD27 (especially Tregs modulation) to the antitumour activity of cusatuzumab remain insufficiently defined and may vary across tumour types depending on immune contexture and tumour biology.55, 56, 58. This evidence concerns the gene CD70 and neoplasm.